Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - PLUS THERAPEUTICS, INC. | d910399dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 13, 2015
CYTORI THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-34375 | 33-0827593 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
3020 Callan Road, San Diego, California 92121
(Address of principal executive offices, with zip code)
(858) 458-0900
(Registrant’s telephone number, including area code)
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events
On April 13, 2015, Cytori Therapeutics, Inc. (the “Company”) issued a press release announcing preliminary top-line 12 month follow-up data from the 12 patient investigator initiated Scleradec-I trial clinical trial conducted by Professor B. Granel and Professor G. Magalon from the Assistance Publique des Hôpitaux de Marseille. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number |
Description | |
| Exhibit 99.1 | Cytori Therapeutics, Inc. Press Release, dated April 13, 2015 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CYTORI THERAPEUTICS, INC. | ||||||
| Date: April 13, 2015 | By: /s/ Tiago Girao | |||||
| Tiago Girao | ||||||
| VP Finance and Chief Financial Officer | ||||||
Exhibit Index
| Exhibit Number |
Description | |
| Exhibit 99.1 | Cytori Therapeutics, Inc. Press Release, dated April 13, 2015 | |